Form 4: Gilead Sciences Executive Deborah Telman Reports Routine Equity Transactions

Gilead Sciences' EVP, Corporate Affairs & General Counsel, Deborah H. Telman, reported the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Summary

• Deborah H. Telman, Executive Vice President, Corporate Affairs & General Counsel of Gilead Sciences, Inc. (GILD), reported transactions on June 10, 2025.
• She acquired 1,313 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs).
• Concurrently, she disposed of 430 shares of common stock at a price of $110.09 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Ms. Telman directly beneficially owns 37,801 shares of Gilead Sciences common stock.
• She also holds 30,389 unvested Restricted Stock Units.
• Each Restricted Stock Unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
• The Restricted Stock Units have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date, and the balance vesting 6.25% quarterly thereafter until fully vested.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document reports routine executive compensation transactions (RSU vesting and tax-related sale), which are standard and do not inherently indicate a strong positive or negative outlook for the company.

Positives

• The acquisition of 1,313 shares through RSU vesting demonstrates continued equity participation by a key executive, aligning management's interests with long-term shareholder value.
• The structured vesting schedule of the Restricted Stock Units (25% on first anniversary, then 6.25% quarterly) incentivizes long-term commitment and performance from the executive.

Negatives

• The disposition of 430 shares, while for tax purposes, represents a reduction in the executive's direct common stock holdings.

Future Outlook

The document indicates future share acquisitions for the executive as the remaining 30,389 Restricted Stock Units continue to vest according to their four-year schedule.

Industry Context

This Form 4 filing details a routine executive compensation event, common across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where long-term equity incentives like Restricted Stock Units are a standard component of executive remuneration.

Related Party Transactions

• The reported transactions are related party dealings, as they involve an executive (Deborah H. Telman) of Gilead Sciences, Inc. acquiring and disposing of company securities as part of her compensation.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive equity ownership and compensation practices, which can influence investor confidence.
• Employees: Reflects standard executive compensation structures within the company, potentially impacting morale and retention strategies for other employees with similar equity incentives.

Next Steps

• Continued vesting of the remaining 30,389 Restricted Stock Units held by Deborah H. Telman, with 25% vesting on the first anniversary of the grant date and 6.25% quarterly thereafter until fully vested.

Key Dates

Keywords

Gilead Sciences, GILD, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Common Stock, Deborah H. Telman